PDL BioPharma Inc. (NASDAQ:PDLI) increased 3.75% to close at $5.81. PDLI traded 5.76 million shares for the day and its earning per share remained $0.85. PDL BioPharma, Inc. engages in the management of antibody humanization patents and royalty assets, which consist of Queen et al. patents and license agreements with various biotechnology and pharmaceutical companies. Its Queen et al. patents primarily cover humanized antibodies, methods for humanizing antibodies, polynucleotide encoding in humanized antibodies, and methods of producing humanized antibodies. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.

Amgen, Inc. (NASDAQ:AMGN) decreased 1.00% to close at $51.39. AMGN traded 5.44 million shares for the day and its earning per share remained $4.79. Amgen Inc., a biotechnology medicines company, discovers, develops, manufactures, and delivers human therapeutics based on advances in cellular and molecular biology primarily in the United States, Europe, and Canada. The company markets primarily recombinant protein therapeutics in supportive cancer care, nephrology, and inflammation. Its principal products include Aranesp and EPOGEN erythropoietic-stimulating agents that stimulate the production of red blood cells.

Teva Pharmaceutical Industries Ltd (ADR) (NASDAQ:TEVA) increased 1.78% to close at $50.82. TEVA traded 4.79 million shares for the day and its earning per share remained $3.66. Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, produces, and markets generic drugs in various therapeutic categories worldwide. It offers generic pharmaceutical products in a range of dosage forms, such as tablets, capsules, ointments, creams, liquids, injectables, and inhalants. The company also provides branded products, including Copaxone to treat multiple sclerosis; and Azilect to treat Parkinson’s disease. The company was founded in 1901 and is headquartered in Petach Tikva, Israel.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

Teva Pharmaceutical Industries Ltd (ADR) (NASDAQ:TEVA) decreased 0.34% to close at $49.11. TEVA traded 6.25 million shares for the day and its earning per share remained $3.25. Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical company that develops, produces and markets generic drugs covering all treatment categories. The Company has a pharmaceutical business, whose principal products are Copaxone for multiple sclerosis and Azilect for Parkinson’s disease, respiratory products and women’s health products. On January 29, 2009, the Company sold its Israeli animal health product line to Phibro Animal Health Corporation.

Amgen, Inc. (NASDAQ:AMGN) decreased 0.61% to close at $53.40. AMGN traded 4.07 million shares for the day and its earning per share remained $4.63. Amgen Inc. (Amgen) is an independent biotechnology medicines company. The Company discovers, develops, manufactures and markets medicines for grievous illnesses. It focuses on human therapeutics and concentrates on medicines based on advances in cellular and molecular biology. Its principal products include Aranesp (darbepoetin alfa) and EPOGEN (Epoetin alfa), erythropoietic-stimulating agents (ESAs) that stimulate the production of red blood cells; an inhibitor of tumor necrosis factor (TNF), a substance that plays a role in the body’s response to inflammatory diseases.

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) increased 7.07% to close at $4.39. ARIA traded 2.61 million shares for the day and its earning per share remained $0.88. ARIAD Pharmaceuticals, Inc. (ARIAD) is a biopharmaceutical company focused on the discovery and development of drugs to provide therapeutic intervention in treating human diseases at the cellular level. The Company’s lead cancer product candidate, ridaforolimus, is an internally discovered, potent inhibitor of the protein mTOR. Its third product candidate, AP26113, is an investigational anaplastic lymphoma kinase (ALK), including non-small cell lung cancer, lymphoma and neuroblastoma.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

American Video Teleconferencing Corp. (Pink Sheets:AVOT) is pleased to announce that it has signed an option agreement to acquire two claim blocks in townships of Mekinac and Lajuene, Province of Quebec.

These claim blocks are approximately 3600 acres in total and are located 120 miles east of Montreal P.Q. and 50 miles north of Three Rivers P.Q. They are accessible year round with infrastructure in the immediate vicinity. The claims adjoin a property that had one of the highest readings of Rare Earths in North America. Sampling in the 1950s gave readings of 48% combined Cerium, Lanthanum, Neoymium and Yttrium. That property has remained dormant for over 50 years but the new owners plan an extensive exploration program this fall.

The company, after a lengthy search and after careful due diligence, believes this is going to be one of the most active areas for Rare Earths exploration and our holdings are in the same geological setting as the 48% Rare Earths showing. Rare Earths are in huge demand especially in the United States as China is closing off its exports of these strategic metals to less than 5% of its production.

The company will aggressively continue to search world wide for opportunities in Precious, Base and Rare Earths metal projects.

*************************************************

QUALCOMM Incorporated (Nasdaq:QCOM) announced the immediate availability of its Augmented Reality (AR) Extension for Unity. Qualcomm’s AR Extension for Unity will enable developers to use Unity’s award-winning game development tool to rapidly build augmented reality applications for Android smartphones. Building upon Qualcomm’s existing AR platform for Android, the Extension, combined with the Unity development platform, expands the options available and allows developers to build richer interactive games and applications with shorter development times. Our mission at Unity Technologies is to democratize game development by making best-of-breed enabling technologies accessible to the broader developer community,” said David Helgason, co-founder and CEO of Unity Technologies. “We continue to deliver on this mission by supporting Qualcomm’s AR platform for Android application development and are excited by the potential for AR games and experiences.

QUALCOMM Incorporated engages in the development, design, manufacture, and marketing of digital wireless telecommunications products and services. The company operates in four segments: Qualcomm Code Division Multiple Access Technologies (QCT), Qualcomm Technology Licensing (QTL), Qualcomm Wireless and Internet (QWI), and Qualcomm Strategic Initiatives (QSI).

*************************************************

Intuit Inc. (Nasdaq:INTU) CEO Brad Smith was honored to play a role in the U.S.-India Business Council (USIBC) Presidential Executive Mission to India. Smith joined other private and public sector leaders from the United States and India to discuss innovation, education, and removing barriers to economic and commercial cooperation. Smith participated in a panel discussion titled “Next Generation Leadership: The Future of Innovation and Entrepreneurship,” which directly preceded an address by U.S. President Barack Obama. Recognized for Intuit’s success in creating innovative solutions to help small businesses grow and thrive, Smith discussed the importance of innovation and collaboration to build a strong knowledge partnership between the United States and India.

Intuit Inc. provides business and financial management solutions for small and medium sized businesses, consumers, accounting professionals, and financial institutions in the United States, Canada, and the United Kingdom.

*************************************************

Teva Pharmaceutical Industries Limited (Nasdaq:TEVA) will host a live audio webcast at the Credit Suisse 2010 Healthcare Conference with William Marth, President & CEO, Teva Pharmaceuticals - Americas, presenting on Thursday, November 11, 2010 at 4:00pm EST. Live over the Internet — log on to the Web and register for the event.

Teva Pharmaceutical Industries Limited engages in the development, production, and sale of a range of generic and branded pharmaceuticals, biogenerics, and active pharmaceutical ingredients (APIs) worldwide.

*************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.Crown Equity Holdings Inc. (CRWE.OB) anticipates to receive 2,000,000 shares of (144) restricted common stock of American Video Teleconferencing Corp. (AVOT.PK) from the company for 12 months IR Services

**************************************************************

PROTEONOMIX, INC. (PROT.OB), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, applauds the actions taken by the Costa Rican Ministry of Health to crack down on unauthorized stem cell clinics. The chief of the ministry’s research council, Dr. Ileana Herrera, stated, “If (stem cell treatment’s) efficacy and safety has not been proven, we don’t believe it should be used.”

Mr. Michael Cohen, Chairman and CEO of Proteonomix, stated, “We have no doubt that stem cell therapies will be a major factor in combatting a variety of medical conditions but it is essential that it be undertaken only after the clinical results determine that such a course of action is efficacious. Too much hype about cures for all types of diseases is diminishing the potential value of stem cells and could unduly delay future progress in stem cell treatments and research. Medical tourism is not a dirty word, if established in an ethical and professional manner.”

Cohen added, “At Proteonomix we have adopted a rigorous and cautious approach that will ensure that patients that are ultimately treated by us have confidence that the procedures will be safe, relatively low cost and offering the best chance for alleviating their specific medical condition. Our research progress has been dramatic and the procedures and intellectual property portfolio, made up of a significant number of pending patents, have resulted in Proteonomix emerging as a leader in the development of stem cell medical treatments.”

“The mission of one of our subsidiaries, Proteonomix Regenerative Translational Medicine Institute, Inc. (’PRTMI’), is to translate the most promising internal and external stem cell biology and cellular therapy to clinical applications of regenerative medicine. PRTMI will undertake the creation of a global, single standard, cellular laboratory that will seek to create a seamless transition between laboratories and patient care facilities.”

Mr. Cohen concluded, “We view joint ventures with appropriate strategic partners as a key to the success of Proteonomix and, at the appropriate time, anticipate that PRTMI will engage in such discussions.”

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC), is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders. Three product candidates are in clinical development:

Sapacitabine (CYC682), a cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes and lung cancer.

Seliciclib (CYC202 or R-roscovitine), a CDK (cyclin dependent kinase) inhibitor, is in Phase 2 studies for the treatment of lung cancer and nasopharyngeal cancer and in a Phase 1 trial in combination with sapacitabine.

CYC116, an Aurora kinase and VEGFR2 inhibitor, is in a Phase 1 trial in patients with solid tumors.

Cyclacel’s ALIGN Pharmaceuticals subsidiary markets directly in the U.S., Xclair® Cream for radiation dermatitis, Numoisyn® Liquid and Numoisyn® Lozenges for xerostomia. Cyclacel’s strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a portfolio of commercial products and a development pipeline of novel drug candidates.

Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) commented recently on the U.S. Food and Drug Administration’s response to a citizen petition questioning the approval criteria for a generic Lovenox® (enoxaparin sodium) injection and its subsequent approval of another generic filer’s Abbreviated New Drug Application (ANDA).

After reviewing the FDA’s response to the citizen petition, which outlines 5 criteria to demonstrate “sameness”, Teva believes that it has demonstrated to the FDA that its version of generic Lovenox meets their criteria and that Teva’s pending ANDA is approvable.

Teva maintains the approval for an ANDA for generic Lovenox is appropriate because:
- The active ingredient in enoxaparin is significantly better characterized than the active ingredients of significantly more complex molecules
- Pharmacologically active portions of enoxaparin can be identified and replicated, and
- In vitro and in vivo PD tests are rapidly indicative of drug efficacy and safety

Teva recognizes and supports FDA authority and discretion to make generic drug approvals on a case-by-case basis considering drug complexity, patient efficacy and safety outcomes.

Given the complexity of Teva’s Copaxone® and the serious, degenerative nature of multiple sclerosis, it is Teva’s belief that any potential generic version of Copaxone should be evaluated via pre-clinical and full-scale, placebo-controlled clinical trials with measured clinical endpoints in multiple sclerosis patients to establish safety, efficacy and immunogenicity in a real patient population.

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 15 pharmaceutical companies in the world and is the leading generic pharmaceutical company. The company develops, manufactures and markets generic and innovative pharmaceuticals and active pharmaceutical ingredients. Over 80 percent of Teva’s sales are in North America and Western Europe.

**************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer ) . Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has received twenty thousand dollars in cash and twenty thousand dollars in free trading shares from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (PROT.OB)

**************************************************************

Power3 Medical Products, Inc. (OTCBB: PWRM) announced that, in collaboration with Lourdes R. Bosquez, MD, it has unexpectedly discovered new and unprecedented findings regarding clinically important differences in the response of the NuroPro® protein biomarkers in the blood of untreated Alzheimer’s disease patients compared to patients treated with the widely used anti-dementia drugs Aricept® (Donepezil HCl, Pfizer – NYSE: PFE), Exelon® (Rivastigmine, Novartis – NYSE: NVS), and Namenda® (Memantine HCl, Forest Laboratories – NYSE: FRX). These results relate to the genetically distinct groups of Alzheimer’s disease patients, i.e., those individuals who possess the Alzheimer’s high-risk gene for Apolipoprotein E4 and those who do not possess the gene.

NuroPro® was originally indicated for diagnostics to determine whether or not a patient had Alzheimer’s disease. With these results, NuroPro® now extends into the pharmaceutical arena due to its ability to predict and monitor the response to drug treatment, including the underlying disease process and the insidious progression of irreversible neurological damage, even in the face of temporary improvements in cognition and other symptoms.

Power3 has filed for patent protection for these findings and will be publishing these seminal results in the near future in one of the world’s most prestigious peer-reviewed scientific journals. Power3 also plans to demonstrate the clinical application and benefits of its NuroPro® diagnostic tests to healthcare providers located throughout the world. Power3 believes that this will assist the company greatly in an effort to generate sales of its NuroPro® diagnostic tests. Power3 is currently working on a joint distribution effort with a number of potential business partners, such as the companies mentioned above, for the sale of its NuroPro® diagnostic tests and the development of new drugs.

“This new and amazing discovery will help clarify some of the clinical observations and overcome difficulties that we have had as physicians, not only by helping us choose more appropriate treatment and better predict response, but also by helping us find more permanent treatments for the dementias,” said Dr. Bosquez.

Ira L. Goldknopf, Ph.D., President and Chief Scientific Officer of Power3, stated, “This innovation will provide physicians with an invaluable perspective to use in the treatment of their patients and will have profound implications for the diagnosis and treatment of Alzheimer’s disease, and for other diseases as well.”

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) commented recently on the U.S. Food and Drug Administration’s response to a citizen petition questioning the approval criteria for a generic Lovenox® (enoxaparin sodium) injection and its subsequent approval of another generic filer’s Abbreviated New Drug Application (ANDA).

After reviewing the FDA’s response to the citizen petition, which outlines 5 criteria to demonstrate “sameness”, Teva believes that it has demonstrated to the FDA that its version of generic Lovenox meets their criteria and that Teva’s pending ANDA is approvable.

Teva maintains the approval for an ANDA for generic Lovenox is appropriate because:
- The active ingredient in enoxaparin is significantly better characterized than the active ingredients of significantly more complex molecules
- Pharmacologically active portions of enoxaparin can be identified and replicated, and
- In vitro and in vivo PD tests are rapidly indicative of drug efficacy and safety

Teva recognizes and supports FDA authority and discretion to make generic drug approvals on a case-by-case basis considering drug complexity, patient efficacy and safety outcomes.

Given the complexity of Teva’s Copaxone® and the serious, degenerative nature of multiple sclerosis, it is Teva’s belief that any potential generic version of Copaxone should be evaluated via pre-clinical and full-scale, placebo-controlled clinical trials with measured clinical endpoints in multiple sclerosis patients to establish safety, efficacy and immunogenicity in a real patient population.

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 15 pharmaceutical companies in the world and is the leading generic pharmaceutical company. The company develops, manufactures and markets generic and innovative pharmaceuticals and active pharmaceutical ingredients. Over 80 percent of Teva’s sales are in North America and Western Europe.

Medical Alarm Concepts Holding, Inc. (OTCBB:MDHI), manufacturer of the MediPendant™, the first fully-monitored medical alarm system that allows you to speak and listen directly through the pendant, announces the availability of a new video interview with the Company’s CEO Howard Teicher. The video also includes a demonstration of the superior features, functions and benefits of the revolutionary MediPendant.

“We are extremely excited about the potential of the MediPendant. I encourage everyone to watch the video, which provides a strong understanding of why we believe our personal alarm system is superior to anything on the market today. It is very powerful, user-friendly and gives the customers the freedom and peace of mind to be able to communicate in a two-way manner through the pendant with an EMT-certified operator anytime and anywhere within a 600 feet radius of the home base station. No other system offers this capability. We are very optimistic about our future as we continue to expand our distribution partnerships,” said Howard Teicher, CEO of Medical Alarm Concepts.

Medical Alarm Concepts Holdings, Inc. develops and manufactures innovative products and practical solutions within the framework of a vast growing marketplace. Medical Alarm Concepts has built their reputation in the personal emergency response system (”PERS”) and medical alert industry. With patented technology and state-of-the-art services, MAC is uniquely positioned to mobilize the right people, skills and alliances to ensure success and client satisfaction. Medical Alarm Concepts design and support philosophy emphasizes industry best practices, while providing polished and savvy solutions. MAC’s latest innovation is the development of its two-way voice speakerphone pendant technology.

**************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer ) . Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB)